The Primary
Care Companionfor CNS Disorders

Schizophrenia/Schizoaffective Disorders

Letter to the Editor June 1, 2004

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Thomas J. Kim, MD, MPH; H. W. LeBourgeois III, MD

Prim Care Companion J Clin Psychiatry 2004;6(3):136-137

Article Abstract

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis.

Download Free PDF

This PDF is free for all visitors!

Save

Cite

INFORMATION FROM INDUSTRY

AUVELITY is an FDA-approved treatment for adults with MDD. Auvelity, is a rapid-acting antidepressant with a multimodal mechanism, targeting both glutamatergic and monoaminergic pathways. Learn more about how AUVELITY is thought to work and side effects. Please see Important Safety Information within this document and the full Prescribing Information.

Vol 26 • 2024 • Number 6

Read the Current Issue

Narrative Review

Dextromethorphan-Quinidine for Agitation in Dementia

Original Research

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Original Research

Intervention to Enhance Mental Health Competency

Original Research

Evolution of Treatment Modalities for PTSD

Rounds in the General Hospital

Etiology, Prevention, and Management of TD

Rounds in the General Hospital

Comorbid Bipolar Disorder and PTSD

View current Issue

Letter to the Editor

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

March 20, 2024

As choice of administration route is crucial during psychiatric emergencies, the authors stress the need for RCTs comparing onset of efficacy for agitation across different administration routes of the...

Xintong Mu, Hiroyoshi Takeuchi

Letter to the Editor

Asenapine, Aggression, and Affinity

September 28, 2022

Dr El-Mallakh comments on a recent study by Citrome et al and discusses his group’s research on antiaggression effects of clozapine.

Rif S. El-Mallakh

Letter to the Editor

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

August 3, 2022

This letter comments on methodological aspects of a recent study by Cohen et al.

Florian Naudet, André Gillibert, Barbara Mintzes, et al

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

ELSEWHERE:

FOLLOW US:

Banned, but Not Forgotten: A Case of Ephedrine-Induced Psychosis

Read the Current Issue

Dextromethorphan-Quinidine for Agitation in Dementia

Psychiatric Comorbidities in Adolescents With Polycystic Ovary Syndrome

Intervention to Enhance Mental Health Competency

Evolution of Treatment Modalities for PTSD

Etiology, Prevention, and Management of TD

Comorbid Bipolar Disorder and PTSD

Related Articles

Does the Onset of Efficacy for Agitation Vary Depending on the Administration Route of Antipsychotics?

Asenapine, Aggression, and Affinity

A Mirror-Image Trial or Smoke and Mirrors? Phase 3b Study on Digital Aripiprazole

Celebrating85 Years

Subscribe to readmore articles

Celebrating
85 Years

Subscribe to read
more articles